2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999

• December 15, 2004

  CYPRESS BIOSCIENCE INC. (NASDAQ: CYPB) To PRESENT AT WACHOVIA SECURITIES 10 FOR ‘O5 BIOTECH CONFERENCE  

• December 8, 2004
  Cypress Completes Enrollment of Phase III Milnacipran Clinical Trial Results Expected Fall 2005
• December 7, 2004
  CYPRESS BIOSCIENCE INC. (NASDAQ: CYPB) TO PRESENT AT FIRST ALBANY CAPITAL ANNUAL GROWTH CONFERENCE
• November 30, 2004
  CYPRESS BIOSCIENCE INC. (NASDAQ: CYPB) TO PRESENT AT LAZARD LIFE SCIENCES CONFERENCE
• November 18, 2004
  CYPRESS BIOSCIENCE INC. (NASDAQ: CYPB) TO PRESENT AT GRANITE FINANCIAL GROUP HEALTHCARE INVESTORS CONFERENCE
• November 9, 2004
  CYPRESS BIOSCIENCE, INC. ANNOUNCES THIRD QUARTER 2004 RESULTS AND COMMENCEMENT OF SECOND PHASE III TRIAL
• November 8, 2004
  CYPRESS BIOSCIENCE INC. (NASDAQ: CYPB) TO PRESENT AT CIBC WORLD MARKETS HEALTHCARE CONFERENCE
• October 26, 2004
  CYPRESS BIOSCIENCE INC. (NASDAQ: CYPB) TO PRESENT AT RODMAN & RENSHAW TECHVEST CONFERENCE
• October 11, 2004
  Cypress' "Pain Assessment in Patients with Fibromyalgia Syndrome: A Consideration of Methods for Clinical Trials" Published in Clinical Journal of Pain
• September 28, 2004
  CYPRESS BIOSCIENCE INC. (NASDAQ: CYPB) TO PRESENT AT UBS GLOBAL LIFE SCIENCES CONFERENCE
• September 20, 2004
  CYPRESS BIOSCIENCE INC. (NASDAQ: CYPB) APPOINTS NEW BOARD MEMBERS
• September 9, 2004
  CYPRESS BIOSCIENCE, INC. AND FOREST LABORATORIES, INC. TO COMMENCE THE SECOND PHASE III CLINICAL TRIAL FOR MILNACIPRAN IN THE FOURTH QUARTER
• September 8, 2004
  CYPRESS BIOSCIENCE INC. (NASDAQ: CYPB) TO PRESENT AT BIOCENTURY NEWSMAKERS CONFERENCE
• August 9, 2004
  CYPRESS BIOSCIENCE, INC. ANNOUNCES SECOND QUARTER 2004 RESULTS
• August 3, 2004
  CYPRESS BIOSCIENCE INC. (NASDAQ: CYPB) DRUG MILNACIPRAN HIGHLIGHTED IN TODAY'S WALL STREET JOURNAL FEATURE ON FMS
• July 20, 2004
  CYPRESS BIOSCIENCE INC. (NASDAQ: CYPB) ANNOUNCES NEW MILNACIPRAN MANUFACTURING FACILITY IN FRANCE
• June 21, 2004
  CYPRESS BIOSCIENCE INC. (NASDAQ: CYPB) PHASE II MILNACIPRAN DATA PRESENTED AT CINP CONGRESS IN PARIS
• June 9, 2004
  CYPRESS BIOSCIENCE, INC. LISTED ON CHICAGO BOARD OPTIONS EXCHANGE
• May 18, 2004
  CYPRESS BIOSCIENCE, INC. ADDED TO NASDAQ BIOTECHNOLOGY INDEX
• May 17, 2004
  CYPRESS BIOSCIENCE, INC. ANNOUNCES FIRST QUARTER 2004 RESULTS
• May 11, 2004
  CYPRESS BIOSCIENCE INC. (NASDAQ: CYPB) TO PRESENT AT RODMAN & RENSHAW TECHVEST GLOBAL HEALTHCARE CONFERENCE
• May 4, 2004
  CYPRESS BIOSCIENCE INC. (NASDAQ: CYPB) TO PRESENT AT SMITH BARNEY CITIGROUP 2004 SMALL & MID-CAP CONFERENCE
• May 3, 2004
  CYPRESS BIOSCIENCE INC. (NASDAQ: CYPB) TO PRESENT AT THE DEUTSCHE BANK 29TH ANNUAL HEALTH CARE CONFERENCE
• April 26, 2004
  CYPRESS BIOSCIENCE INC. (NASDAQ: CYPB) TO PRESENT AT THE CIBC ANNUAL BIOTECHNOLOGY & SPECIALTY PHARMACEUTICAL CONFERENCE
• April 7, 2004
  CYPRESS BIOSCIENCE, INC. ANNOUNCES EXERCISE OF OVER-ALLOTMENT OPTION
• April 2, 2004
  CYPRESS BIOSCIENCE, INC. ANNOUNCES PRICING OF COMMON STOCK IN PUBLIC OFFERING
• March 29, 2004
  CYPRESS BIOSCIENCE, INC. ANNOUNCES PUBLIC OFFERING OF 5 MILLION SHARES OF COMMON STOCK
• March 29, 2004
  CYPRESS BIOSCIENCE, INC. ANNOUNCES FOURTH QUARTER AND FISCAL YEAR END 2003 RESULTS
• March 8, 2004
  CYPRESS BIOSCIENCE INC. (NASDAQ: CYPB) TO PRESENT AT THE SG COWEN 24TH ANNUAL HEALTHCARE CONFERENCE
• March 4, 2004
  Cypress Bioscience Inc. (NASDAQ: CYPB) to Present at the Jump Start to Products Conference
• March 1, 2004
  CYPRESS BIOSCIENCE INC. (NASDAQ: CYPB) APPROVED FOR LISTING ON NASDAQ NATIONAL MARKET
• February 19, 2004
  BIO CEO Panel to Address Faster, Lower Risk and Higher Return Approaches to Drug R&D at Annual BIO Industry CEO and Investor Conference
• February 17, 2004
  Cypress Bioscience Inc. (NASDAQ: CYPB) to Present at the Roth Capital Partners 16th Annual Growth Stock Conference
• January 26, 2004
  Cypress Bioscience, Inc. Licenses Collegium Pharmaceutical’s Milnacipran Patent Portfolio
• January 9, 2004
  Cypress Bioscience, Inc., Forest Laboratories, Inc. and Pierre Fabre Medicament Announce Development and Marketing Agreement for Milnacipran